These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38940039)

  • 1. The Cytoprotective and Cytotoxic Functions of Autophagy in Response to mTOR Inhibitors.
    Elshazly AM; Elzahed AA; Gewirtz DA
    Front Biosci (Landmark Ed); 2024 Jun; 29(6):231. PubMed ID: 38940039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches.
    Ihlamur M; Akgul B; Zengin Y; Korkut ŞV; Kelleci K; Abamor EŞ
    Curr Mol Med; 2024; 24(4):478-494. PubMed ID: 37165594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB; Bivona C; Medina PJ
    Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
    Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
    Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
    Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
    Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and molecular effects of the mTOR inhibitor everolimus.
    Saran U; Foti M; Dufour JF
    Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo.
    Liu W; Huang S; Chen Z; Wang H; Wu H; Zhang D
    Pathol Res Pract; 2014 Nov; 210(11):764-9. PubMed ID: 24767255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
    Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
    Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
    Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
    Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma.
    Rosich L; Colomer D; Roue G
    Autophagy; 2013 Jan; 9(1):115-7. PubMed ID: 23079699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR signaling and drug development in cancer.
    Dancey J
    Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mTOR pathways in human malignancies.
    Fasolo A; Sessa C
    Curr Pharm Des; 2012; 18(19):2766-77. PubMed ID: 22475451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of induced autophagy increases apoptosis of Nara-H cells.
    Nakamura O; Hitora T; Akisue T; Kawamoto T; Yamagami Y; Yamamoto T
    Int J Oncol; 2011 Dec; 39(6):1545-52. PubMed ID: 21805033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.
    Xie X; White EP; Mehnert JM
    PLoS One; 2013; 8(1):e55096. PubMed ID: 23383069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting a mTOR/autophagy axis: a double-edged sword of rapamycin in spontaneous miscarriage.
    Li MY; Shen HH; Cao XY; Gao XX; Xu FY; Ha SY; Sun JS; Liu SP; Xie F; Li MQ
    Biomed Pharmacother; 2024 Aug; 177():116976. PubMed ID: 38906022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.